Arcellx (ACLX) Stock Forecast & Price Target

$89.21 +1.99 (+2.28%)

(As of 01:00 PM ET)

Arcellx - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 14 Analyst Ratings

Sell
0

Hold
0

Buy
14

Based on 14 Wall Street analysts who have issued ratings for Arcellx in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 13 have given a buy rating, and 1 has given a strong buy rating for ACLX.

Consensus Price Target

$103.08
15.54% Upside

According to the 14 analysts' twelve-month price targets for Arcellx, the average price target is $103.08. The highest price target for ACLX is $136.00, while the lowest price target for ACLX is $73.00. The average price target represents a forecasted upside of 15.54% from the current price of $89.21.

Get the Latest News and Ratings for ACLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arcellx and its competitors.

ACLX Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$103.08	$89.75	$78.00	$54.77
Forecasted Upside	15.54% Upside	-0.78% Downside	12.42% Upside	2.60% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Man behind OpenAI makes shocking new bet (Ad)

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

Check out our report right here.

ACLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arcellx Stock vs. The Competition

Type	Arcellx	Medical Companies	S&P 500
Consensus Rating Score	3.07	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	18.18% Upside	26,931.56% Upside	9.82% Upside
News Sentiment Rating	Positive News See Recent ACLX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	Truist Financial 2 of 5 stars		Boost Target	Buy ➝ Buy	$87.00 ➝ $136.00	+32.36%
11/8/2024	Piper Sandler 2 of 5 stars	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$91.00 ➝ $115.00	+15.97%
11/6/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$96.00 ➝ $96.00	+10.19%
11/6/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $95.00	+9.04%
11/6/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$77.00 ➝ $106.00	+21.67%
11/6/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$84.00 ➝ $100.00	+14.78%
Man behind OpenAI makes shocking new bet (Ad) Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously. Check out our report right here.
11/6/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$81.00 ➝ $106.00	+21.67%
10/18/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ben Burnett Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$83.00 ➝ $122.00	+28.60%
10/17/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$85.00 ➝ $115.00	+25.68%
10/8/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Q. Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$109.00	+43.29%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$85.00	+70.79%
4/4/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$82.00	+29.75%
2/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$62.00 ➝ $73.00	+8.44%
10/30/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
10/17/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$52.00	+52.67%
10/12/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Graybosch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/24/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$45.00 ➝ $58.00	+45.22%
3/30/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$35.00 ➝ $39.00	+27.74%
3/30/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$35.00 ➝ $39.00	+25.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:28 PM ET.

ACLX Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Arcellx is $103.08, with a high forecast of $136.00 and a low forecast of $73.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares.
: According to analysts, Arcellx's stock has a predicted upside of 15.54% based on their 12-month stock forecasts.
: Arcellx has been rated by research analysts at Bank of America, Canaccord Genuity Group, Cantor Fitzgerald, HC Wainwright, Morgan Stanley, Needham & Company LLC, Piper Sandler, Redburn Atlantic, Robert W. Baird, Stifel Nicolaus, and Truist Financial in the past 90 days.
: Analysts like Arcellx more than other "medical" companies. The consensus rating for Arcellx is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ACLX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:ACLX) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcellx (ACLX) Stock Forecast & Price Target